Alzheimer’s drug donanemab: what promising trial means for treatments

Sara Reardon

Nature, 2023, vol. 617, issue 7960, 232-233

Abstract: Results suggest that the amyloid-targeting drug candidate slows cognitive decline in some people, but questions remain over its potential side effects.

Keywords: Brain; Drug discovery; Alzheimer's disease (search for similar items in EconPapers)
Date: 2023
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-023-01537-5 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:617:y:2023:i:7960:d:10.1038_d41586-023-01537-5

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-023-01537-5

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().